Skip to main content
Clinical Trials/NCT02398188
NCT02398188
Completed
Phase 3

A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects

Evofem Inc.35 sites in 1 country793 target enrollmentApril 9, 2015

Overview

Phase
Phase 3
Intervention
LIPO-202
Conditions
Central Abdominal Bulging
Sponsor
Evofem Inc.
Enrollment
793
Locations
35
Primary Endpoint
Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

Registry
clinicaltrials.gov
Start Date
April 9, 2015
End Date
October 29, 2015
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy male or non-pregnant female subjects
  • Capable of providing written consent.
  • BMI \< 30 kg/m2
  • Stable diet and exercise routine
  • Central abdominal bulging that is evaluated by the clinician at least slight bulge, not flat

Exclusion Criteria

  • Have had any treatment of the fat around your abdomen, including surgical procedures (tummy tuck, liposuction), injections for fat loss or treatments with devices to reduce fat in your abdomen.
  • Plan on starting a weight loss or exercise program during the study.
  • Known hypersensitivity to study drugs

Arms & Interventions

LIPO-202

Experimental arm

Intervention: LIPO-202

Placebo

Placebo comparator

Intervention: Placebo

Outcomes

Primary Outcomes

Percentage of Subjects Who Achieved a Composite P-GAPS1/CPnS2 Response

Time Frame: Baseline and End of Study (1 week post last treatment, 9 weeks after first treatment)

The composite P-GAPS1/CPnS2 response was defined as at least a 1 point (grade) improvement in P-GAPS and at least a 2 point (grade) improvement in CPnS from baseline after 8 weeks of treatment. Patient - Global Abdominal Perception Scale (P-GAPS) - a patient views and assesses the contour of their abdomen on a 5-point verbal scale ranging from "Flat" to "Big Bulge". Clinician Photonumeric Scale (CPnS) - a trained clinician rater examines the subject's abdomen and matches the subject's abdominal bulge/profile to the nearest gender-specific abdominal photo on the 6-point scale.

Percent Change in the Patient Reported Global Abdominal Perception Score

Time Frame: 8 weeks post the start of treatment

1 equals much improved, 7 equals much worse. The higher the scores the worse the outcome.

Secondary Outcomes

  • Percent Change in Waist Circumference(8 weeks post the start of treatment)

Study Sites (35)

Loading locations...

Similar Trials